Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-randomized Controlled, Prospective, Real-world Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

NCT07553767 is registered in ClinicalTrials.gov with Ningbo No.2 Hospital as lead sponsor.

NCT NCT07553767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07553767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-randomized Controlled, Prospective, Real-world Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
Lead sponsor
Ningbo No.2 Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
December 31, 2035
Enrollment
156 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b chronic, hepatitis b chronic infection, hepatocellular carcinoma